RxDoctor Payments Data

Debbie Fibel, MD

Internal Medicine · Lexington, KYNPI 1891770301

Payments from drug & device makers

$720in general payments, 2019–2025

Across 54 payments — averaging $13.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$148
  • Pfizer$142
  • Novartis$110
  • Novo Nordisk$61
  • Otsuka America Pharmaceutical, Inc.$37
  • Johnson & Johnson$35
  • plus $187 from 9 others

What the payments were for

  • Food & beverage$720100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$720 in reported general payments places this provider in the 55th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$75,423
Medicare patients
167
Services billed
1,152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$95,481
EliquisApixaban60$58,188
XareltoRivaroxaban50$47,084
JardianceEmpagliflozin45$46,274
JanuviaSitagliptin Phosphate29$28,285
Tresiba Flextouch U-200Insulin Degludec18$25,053
MounjaroTirzepatide16$16,709
Repatha SureclickEvolocumab16$14,021
ArexvyRsvpref3 Antigen/As01e/Pf39$12,224
LinzessLinaclotide15$8,959
Tresiba Flextouch U-100Insulin Degludec11$8,475
EntrestoSacubitril/Valsartan12$7,756
Rosuvastatin Calcium455$5,756
InvokanaCanagliflozin12$5,607
PremarinEstrogens, Conjugated15$4,404

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$61$95,48180 claims
PfizerEliquis, Premarin$142$62,59275 claims
Johnson & JohnsonXarelto, Invokana$35$52,69262 claims
Boehringer IngelheimJardiance$34$46,27445 claims
Lilly USA, LLCMounjaro$26$16,70916 claims
NovartisEntresto$110$7,75612 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$11$2,595223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →